MedPath

A Study of ABT-751 in Patients With Renal Cell Cancer

Phase 2
Completed
Conditions
Renal Cell Cancer
Registration Number
NCT00073112
Lead Sponsor
Abbott
Brief Summary

The purpose of the study is to determine if ABT-751 will decrease tumors, and determine how long the tumor shrinkage can be maintained in patients with renal cell cancer. Patients will receive ABT-751 by mouth daily for 21 days. Patients will be off drug for 7 days before starting the next cycle of drug.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
60
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Objective Response Rate in subjects with RCC1 year
Secondary Outcome Measures
NameTimeMethod
Time to Tumor Progression (TTP)1 year
Survival2 years
Toxicities associated with treatment administration1 year

Trial Locations

Locations (23)

Arizona Cancer Research Center

🇺🇸

Tucson, Arizona, United States

UCLA School of Medicine

🇺🇸

Los Angeles, California, United States

Clinical Trials + Research Associates

🇺🇸

Montebello, California, United States

US Oncology Inc Rocky Mountain Cancer Centers

🇺🇸

Denver, Colorado, United States

Oncology Hematology Group of South Florida

🇺🇸

Miami, Florida, United States

US Oncology Inc Florida Cancer Institute

🇺🇸

New Port Richey, Florida, United States

US Oncology Inc Ocala Oncology Center

🇺🇸

Ocala, Florida, United States

US Oncology Inc Cancer Centers of Florida, P.A.

🇺🇸

Orlando, Florida, United States

University of Chicago Medical Center

🇺🇸

Chicago, Illinois, United States

Sidney Kimmel Comprehensive Cancer Center

🇺🇸

Baltimore, Maryland, United States

Scroll for more (13 remaining)
Arizona Cancer Research Center
🇺🇸Tucson, Arizona, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.